FRNM · FREENOME INC
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Market Cap
1.125B
52 Wk Range
$9.71 - $17.50
Previous Close
$10.09
Open
$10.20
Volume
523,799
Day Range
$9.74 - $10.56
Enterprise Value
897.8M
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
25.01%
Institutional Own.
69.20%
Qtr Updated
N/A
